Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus vs Cyclosporine for Chronic Renal Allograft Failure Risk
NCT00637143Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 1999
- Primary completion
- Feb 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus + Wuzhi capsule in chronic renal allograft failure (CAF) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Graft Survival at 5 years. Started Apr 1999; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
chronic renal allograft failure (CAF)
Beyond the preview
Go deeper on NCT00637143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00637143.